Table 2.

Predictive factors of early and late transfusions after CAR T-cell therapy

A	Transfusion in the early phase (<1 month)
	RBC		Platelets
	aOR (95% CI)	P value	aOR (95% CI)	P value
Age >60 y at infusion	2.06 (1.38-3.07)	.0004	1.61 (1.09-2.38)	.0175
≥1 transfusion (RBC or platelets) within 6 mo before CAR T-cell therapy	9.71 (6.37-14.71)	<.0001	7.35 (4.74-11.49)	<.0001
High (≥2) CAR-HEMATOTOX score	2.01 (1.34-3.01)	.0007	2.42 (1.60-3.66)	<.0001
Treatment with axi-cel (vs tisa-cel)	2.02 (1.34-3.05)	.0008	2.12 (1.40-3.19)	.0004
ECOG PS ≥2 at infusion	2.86 (1.62-5.04)	.0004	2.28 (1.35-3.87)	.0028

B	Transfusion in the late phase (≥1 mo)
	RBC		Platelets
	aOR (95% CI)	P value	aOR (95% CI)	P value
≥1 transfusion (RBC or platelets) within 6 mo before CAR T-cell therapy	5.43 (3.37-8.85)	<.0001	7.75 (4.65-12.99)	<.0001
High (≥2) CAR-HEMATOTOX score	1.98 (1.27-3.09)	.0026	2.15 (1.37-3.37)	.0008
ICANS grade ≥3	3.01 (1.62-5.59)	.0005	NS
Tocilizumab use	NS		1.85 (1.15-2.98)	.0118

The table presents a multivariate analysis.

Factors tested in the multivariate analysis but not predictive were age-adjusted international prognostic index (aaIPI) a diagnostic, refractoriness to firstline treatment, prior autologous stem cell transplantation, chemotherapy within 6 months before CAR T-cell therapy, chemotherapy as bridging therapy, bulky disease (>5 cm) at infusion, CRS grade ≥3, corticosteroids use after CAR T-cell infusion, intensive care unit (ICU) admission after CAR T-cell infusion, erythropoietin (EPO) use after CAR T-cell infusion, and granulocyte-colony stimulating factor (G-CSF) use after CAR T-cell infusion.

NS, non-significant.